We are live on ! Find out more
ANEB

Anebulo Pharmaceuticals
ANEB

Delisted

ANEB was delisted on the 27th of February, 2026.

Back to rankings

9 hedge funds and large institutions have $24.3M invested in Anebulo Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

2.09% more ownership

Funds ownership: 17.95% → 20.03% (+2.1%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

10% less funds holding

Funds holding: 10 → 9 (-1)

18% less capital invested

Capital invested by funds: $29.5M → $24.3M (-$5.21M)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
9
Holders Change
-1
Holders Change %
-10%
% of All Funds
0.15%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
1
Increased
3
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LA
LVW Advisors
New York
+$2.93M
2
TRCT
Tower Research Capital (TRC)
New York
+$26.7K
3
UBS Group
UBS Group
Switzerland
+$3.15K
4
Wells Fargo
Wells Fargo
California
+$4

Top Sellers

Rank Fund Capital Flow
1
LCM
Laurion Capital Management
New York
-$1.48M
2
BlackRock
BlackRock
New York
-$502

ANEB Hedge Fund Activity: Q2 2022 in Review

9 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q2 2022, worth a combined $24.3M — down 18% from $29.5M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of ANEB and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.

The largest buyer was LVW Advisors, opening a new position worth an estimated $2.93M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $1.48M sold.

  • 9 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q2 2022, down from 10 in Q1 2022.
  • Funds reported $24.3M of Anebulo Pharmaceuticals stock for Q2 2022, down 18% quarter-over-quarter.
  • 1 fund opened new Anebulo Pharmaceuticals positions in Q2 2022 and 2 closed out, a net change of -1 holder.
  • The largest Anebulo Pharmaceuticals buyer in Q2 2022 was LVW Advisors, an estimated $2.93M added.
  • The largest Anebulo Pharmaceuticals seller in Q2 2022 was Laurion Capital Management, an estimated $1.48M sold.

Based on aggregated 13F filings for Q2 2022.